We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Ionis Pharmaceuticals Inc | NASDAQ:IONS | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.01 | -0.02% | 41.25 | 41.25 | 50.00 | 1,669 | 12:20:36 |
From May 2019 to May 2024
U.S. pharmaceutical company Genzyme, a unit of French group Sanofi SA (SAN.FR), and Isis Pharmaceuticals Inc. (ISIS) Friday said the Committee for Medicinal Products for Human Use of the European Medicines Agency, the body that authorizes drugs in the European Union, issued a negative opinion for Kynamro, a drug treating homzygous familial hypercholesterolaemia.
MAIN FACTS:
- Genzyme plans to request a re-examination of the negative opinion.
- Genzyme and Isis said an application of Kynamro is currently under review by the U.S. Food and Drug Administration.
- The companies said Kynamro received in October 2012 a positive vote by the FDA advisory panel, which had said the company had provided sufficient efficacy and safety data to support the marketing of the drug for the treatment of patients with homozygous familial hypercholesterolemia
-Write to Inti Landauro at inti.landauro@dowjones.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Ionis Pharmaceuticals Chart |
1 Month Ionis Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
